Table 1.
Demographics at baseline by standard of care medications
| Non-Nephritis trials | Nephritis trials | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| AZA | MMF | MTX | NIS | Total | p | IVC | MMF | Total | p | |
| Total number | 47 | 36 | 42 | 48 | 173 | 321 | 487 | 808 | ||
| Race | ||||||||||
| European | 29 (62%) | 17 (47%) | 29 (69%) | 34 (71%) | 109 (63%) | 0.07 | 125 (39%) | 220 (45%) | 345 (43%) | |
| African | 10 (21%) | 11 (31%) | 6 (14%) | 3 (6%) | 30 (17%) | 27 (8%) | 57 (12%) | 84 (10%) | ||
| *Asian | 5 (11%) | 4 (11%) | 4 (10%) | 10 (21%) | 23 (13%) | 118 (37%) | 155 (32%) | 273 (34%) | 0.04 | |
| Other | 3 (6%) | 4 (11%) | 3 (7%) | 1 (2%) | 11 (6%) | 51 (16%) | 55 (11%) | 106 (13%) | ||
| % Female | 89% | 92% | 90% | 98% | 92% | 0.34 | 85% | 88% | 87% | 0.20 |
| Age (Mean±SD) | 38.5±13.2 | 38.7±12.4 | 41.7±12.5 | 39.0±10.4 | 39.4±12.1 | 0.58 | 31.6±9.9 | 31.1±10.0 | 31.3±9.9 | 0.43 |
| Disease duration (Mean±SD) | 10.6±8.5 | 9.3±7.9 | 5.5±4.3 | N/A† | 8.7±7.6 | 0.04 | 4.9±5.8 | 5.6±5.6 | 5.3±5.7 | 0.09 |
| % with BILAG A at baseline | 53% | 64% | 52% | 58% | 57% | 0.71 | 96% | 94% | 94% | 0.22 |
| Steroid dose‡ (Mean±SD) | 33.7±20.7 | 39.0±23.2 | 34.9±23.5 | 21.7±11.6 | 31.8±20.9 | 0.001 | 34.0±75.3 | 20.3±25.8 | 25.6±51.5 | 0.002 |
AZA: azathioprine; MMF: mycophenolate mofetil; MTX: methotrexate; IVC: intravenous cyclophosphamide; NIS: no immunosuppressant; SD: standard deviation
*
Includes Asian, Pacific Islanders, and American Indians.
†
N/A denotes not available.
‡
Steroid dose includes IV and oral doses.